APA (7th ed.) Citation

Ian M. Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, & James G. Krueger. (2024). Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Ian M. Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, and James G. Krueger. Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Adis, Springer Healthcare, 2024.

MLA (9th ed.) Citation

Ian M. Catlett, et al. Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Adis, Springer Healthcare, 2024.